These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 34050192)
21. Metabolic rescue in pluripotent cells from patients with mtDNA disease. Ma H; Folmes CD; Wu J; Morey R; Mora-Castilla S; Ocampo A; Ma L; Poulton J; Wang X; Ahmed R; Kang E; Lee Y; Hayama T; Li Y; Van Dyken C; Gutierrez NM; Tippner-Hedges R; Koski A; Mitalipov N; Amato P; Wolf DP; Huang T; Terzic A; Laurent LC; Izpisua Belmonte JC; Mitalipov S Nature; 2015 Aug; 524(7564):234-8. PubMed ID: 26176921 [TBL] [Abstract][Full Text] [Related]
22. The use of mitochondria-targeted endonucleases to manipulate mtDNA. Bacman SR; Williams SL; Pinto M; Moraes CT Methods Enzymol; 2014; 547():373-97. PubMed ID: 25416366 [TBL] [Abstract][Full Text] [Related]
23. mitoTev-TALE: a monomeric DNA editing enzyme to reduce mutant mitochondrial DNA levels. Pereira CV; Bacman SR; Arguello T; Zekonyte U; Williams SL; Edgell DR; Moraes CT EMBO Mol Med; 2018 Sep; 10(9):. PubMed ID: 30012581 [TBL] [Abstract][Full Text] [Related]
24. Advances in methods for reducing mitochondrial DNA disease by replacing or manipulating the mitochondrial genome. Rai PK; Craven L; Hoogewijs K; Russell OM; Lightowlers RN Essays Biochem; 2018 Jul; 62(3):455-465. PubMed ID: 29950320 [TBL] [Abstract][Full Text] [Related]
25. TALEN-mediated shift of mitochondrial DNA heteroplasmy in MELAS-iPSCs with m.13513G>A mutation. Yahata N; Matsumoto Y; Omi M; Yamamoto N; Hata R Sci Rep; 2017 Nov; 7(1):15557. PubMed ID: 29138463 [TBL] [Abstract][Full Text] [Related]
26. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure. Soriano V AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352 [TBL] [Abstract][Full Text] [Related]
27. Targeted elimination of mutant mitochondrial DNA in MELAS-iPSCs by mitoTALENs. Yang Y; Wu H; Kang X; Liang Y; Lan T; Li T; Tan T; Peng J; Zhang Q; An G; Liu Y; Yu Q; Ma Z; Lian Y; Soh BS; Chen Q; Liu P; Chen Y; Sun X; Li R; Zhen X; Liu P; Yu Y; Li X; Fan Y Protein Cell; 2018 Mar; 9(3):283-297. PubMed ID: 29318513 [TBL] [Abstract][Full Text] [Related]
28. [MITO-Porter; a cutting-edge technology for mitochondrial gene therapy]. Furukawa R; Yamada Y; Harashima H Yakugaku Zasshi; 2012; 132(12):1389-98. PubMed ID: 23208046 [TBL] [Abstract][Full Text] [Related]
30. Modeling mitochondrial DNA diseases: from base editing to pluripotent stem-cell-derived organoids. Tolle I; Tiranti V; Prigione A EMBO Rep; 2023 Apr; 24(4):e55678. PubMed ID: 36876467 [TBL] [Abstract][Full Text] [Related]
31. Characterization of chemically modified oligonucleotides targeting a pathogenic mutation in human mitochondrial DNA. Tonin Y; Heckel AM; Dovydenko I; Meschaninova M; Comte C; Venyaminova A; Pyshnyi D; Tarassov I; Entelis N Biochimie; 2014 May; 100():192-9. PubMed ID: 23994754 [TBL] [Abstract][Full Text] [Related]
32. Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA. Minczuk M; Papworth MA; Miller JC; Murphy MP; Klug A Nucleic Acids Res; 2008 Jul; 36(12):3926-38. PubMed ID: 18511461 [TBL] [Abstract][Full Text] [Related]
33. Selective elimination of mutant mitochondrial genomes as therapeutic strategy for the treatment of NARP and MILS syndromes. Alexeyev MF; Venediktova N; Pastukh V; Shokolenko I; Bonilla G; Wilson GL Gene Ther; 2008 Apr; 15(7):516-23. PubMed ID: 18256697 [TBL] [Abstract][Full Text] [Related]
34. Modulating mitochondrial quality in disease transmission: towards enabling mitochondrial DNA disease carriers to have healthy children. Diot A; Dombi E; Lodge T; Liao C; Morten K; Carver J; Wells D; Child T; Johnston IG; Williams S; Poulton J Biochem Soc Trans; 2016 Aug; 44(4):1091-100. PubMed ID: 27528757 [TBL] [Abstract][Full Text] [Related]
35. mitoTALEN reduces the mutant mtDNA load in neurons. Bacman SR; Barrera-Paez JD; Pinto M; Van Booven D; Stewart JB; Griswold AJ; Moraes CT Mol Ther Nucleic Acids; 2024 Mar; 35(1):102132. PubMed ID: 38404505 [TBL] [Abstract][Full Text] [Related]
36. Pathogenic Mitochondria DNA Mutations: Current Detection Tools and Interventions. Mustafa MF; Fakurazi S; Abdullah MA; Maniam S Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32059522 [TBL] [Abstract][Full Text] [Related]
37. Trends and prospects in mitochondrial genome editing. Phan HTL; Lee H; Kim K Exp Mol Med; 2023 May; 55(5):871-878. PubMed ID: 37121968 [TBL] [Abstract][Full Text] [Related]
38. A functionally dominant mitochondrial DNA mutation. Sacconi S; Salviati L; Nishigaki Y; Walker WF; Hernandez-Rosa E; Trevisson E; Delplace S; Desnuelle C; Shanske S; Hirano M; Schon EA; Bonilla E; De Vivo DC; DiMauro S; Davidson MM Hum Mol Genet; 2008 Jun; 17(12):1814-20. PubMed ID: 18337306 [TBL] [Abstract][Full Text] [Related]
39. Gene therapy for mitochondrial disorders. Keshavan N; Minczuk M; Viscomi C; Rahman S J Inherit Metab Dis; 2024 Jan; 47(1):145-175. PubMed ID: 38171948 [TBL] [Abstract][Full Text] [Related]
40. Mitochondrial Base Editing: Recent Advances towards Therapeutic Opportunities. Kar B; Castillo SR; Sabharwal A; Clark KJ; Ekker SC Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982871 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]